[144] Cytokinetics Inc. SEC Filing

Rhea-AI Filing Summary

Cytokinetics, Inc. (CYTK) Form 144 notice reports a proposed sale of 6,756 common shares through Morgan Stanley Smith Barney, with an aggregate market value of $238,689.48 based on the filing. The filing lists 119,657,156 shares outstanding and an approximate sale date of 09/02/2025. The shares to be sold were acquired as Restricted Stock Units on 01/03/2022 and payment is marked N/A. The filer also disclosed 10b5-1 sales by Edward Kaye of 3,636 shares on 06/05/2025 for $116,714.87. The document contains standard Rule 144 attestations and a signature block; no relationship to the issuer or additional context is provided in the filing.

Insights

Securities Compliance Specialist

TL;DR: Routine Rule 144 disclosure of a small planned insider sale, with prior 10b5-1 sales also disclosed.

The filing documents a proposed sale under Rule 144 of 6,756 common shares via Morgan Stanley Smith Barney, acquired as RSUs on 01/03/2022. It includes a prior 10b5-1 sale by Edward Kaye of 3,636 shares on 06/05/2025 for $116,714.87. This is a standard regulatory notification ensuring public disclosure of insider sales and planned sales; the filing contains the required attestations but does not provide additional material company information.

Corporate Governance Analyst

TL;DR: Disclosure is compliant and routine; the transactions disclosed are small relative to outstanding shares.

The notice shows the shares were RSUs granted by the issuer and that the seller relies on Rule 144 for the proposed sale dated 09/02/2025. The filing properly lists broker, quantity, and aggregate value and discloses recent 10b5-1 activity. There is no evidence in this document of material corporate developments or governance events beyond normal insider share disposition reporting.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	6756	238689.48	119657156	09/02/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/03/2022	Restricted Stock Units	Issuer			6756	01/03/2022	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for EDWARD KAYE 350 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080	Common	06/05/2025	3636	116714.87

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the CYTK Form 144 disclose about the proposed sale?

The filing discloses a proposed sale of 6,756 common shares with an aggregate market value of $238,689.48, scheduled approximately for 09/02/2025.

How were the shares being sold by the CYTK filer acquired?

The shares were acquired as Restricted Stock Units on 01/03/2022 and the filing lists the acquisition amount as 6,756 shares.

Does the CYTK filing report any recent insider sales?

Yes. It reports 10b5-1 sales by Edward Kaye of 3,636 shares on 06/05/2025, generating gross proceeds of $116,714.87.

Which broker is listed for the proposed CYTK sale?

The broker listed is Morgan Stanley Smith Barney LLC, Executive Financial Services, 1 New York Plaza 8th Floor New York NY 10004.

How many CYTK shares are outstanding according to the filing?

The filing lists 119,657,156 shares outstanding.